| Q37321859 | Advances in antisense oligonucleotide development for target identification, validation, and as novel therapeutics. |
| Q34317280 | An autonomous molecular computer for logical control of gene expression |
| Q36065956 | Antisense approaches for inhibiting respiratory syncytial virus |
| Q36458427 | Antisense-based cancer therapeutics: are we there yet? |
| Q29998947 | Formation of Oligonucleotide Adducts in Pharmaceutical Formulations |
| Q33285354 | High-content imaging analysis of the knockdown effects of validated siRNAs and antisense oligonucleotides |
| Q35997754 | Interfering with cancer: a brief outline of advances in RNA interference in oncology |
| Q83181725 | Intravenous infusion of an antisense oligonucleotide results in exon skipping in muscle dystrophin mRNA of Duchenne muscular dystrophy |
| Q36280813 | Keynote review: the adipocyte as a drug discovery target |
| Q35986039 | Natural and engineered nucleic acids as tools to explore biology |
| Q36904500 | New perspectives on the treatment of differentiated thyroid cancer |
| Q36124734 | Oligonucleotides and polyribonucleotides: a review of antiviral activity |
| Q36385492 | Preclinical anticancer activity of DNA-based cleavage molecules |
| Q29615183 | RNA and disease |
| Q47793021 | Sticky wickets in lower nephron nephrosis |
| Q37423243 | The chemical biology of aptamers |